Total Payments
$1.9M
2024 Payments
$767,048
Companies
32
Transactions
2,722
Medicare Patients
3,515
Medicare Billing
$351,360
Payment Breakdown by Category
Other$1.4M (76.6%)
Consulting$179,155 (9.5%)
Travel$166,887 (8.8%)
Food & Beverage$65,845 (3.5%)
Research$29,007 (1.5%)
Education$169.16 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 501 | 76.1% |
| Consulting Fee | $179,155 | 78 | 9.5% |
| Travel and Lodging | $166,887 | 396 | 8.8% |
| Food and Beverage | $65,845 | 1,720 | 3.5% |
| Unspecified | $29,007 | 16 | 1.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,975 | 6 | 0.6% |
| Education | $169.16 | 4 | 0.0% |
| Honoraria | $8.11 | 1 | 0.0% |
Payments by Type
General
$1.9M
2,706 transactions
Research
$29,007
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $402,181 | 557 | $0 (2024) |
| Dermavant Sciences, Inc. | $221,151 | 258 | $0 (2024) |
| Lilly USA, LLC | $196,549 | 277 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $194,396 | 213 | $0 (2024) |
| LEO Pharma Inc. | $141,747 | 199 | $0 (2024) |
| Amgen Inc. | $128,642 | 149 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $120,776 | 153 | $0 (2024) |
| GENZYME CORPORATION | $85,920 | 90 | $0 (2024) |
| Incyte Corporation | $82,773 | 125 | $0 (2024) |
| UCB, Inc. | $78,232 | 120 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $767,048 | 913 | ABBVIE INC. ($131,278) |
| 2023 | $625,505 | 868 | AbbVie Inc. ($120,928) |
| 2022 | $461,265 | 737 | ABBVIE INC. ($145,917) |
| 2021 | $33,731 | 202 | PFIZER INC. ($14,379) |
| 2020 | $38.47 | 1 | Regeneron Healthcare Solutions, Inc. ($38.47) |
| 2017 | $66.61 | 1 | Genentech USA, Inc. ($66.61) |
All Payment Transactions
2,722 individual payment records from CMS Open Payments — Page 1 of 109
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $55.63 | General |
| 12/27/2024 | Galderma Laboratories, L.P. | — | Travel and Lodging | Cash or cash equivalent | $571.20 | General |
| 12/27/2024 | Galderma Laboratories, L.P. | — | Travel and Lodging | Cash or cash equivalent | $289.30 | General |
| 12/27/2024 | Galderma Laboratories, L.P. | — | Travel and Lodging | Cash or cash equivalent | $252.51 | General |
| 12/27/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $36.40 | General |
| 12/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,930.00 | General |
| Category: Inflammation | ||||||
| 12/23/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $23.25 | General |
| 12/23/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $7.86 | General |
| Category: DERMATOLOGY | ||||||
| 12/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Travel and Lodging | In-kind items and services | $1,093.71 | General |
| Category: DERMATOLOGY | ||||||
| 12/19/2024 | Galderma Laboratories, L.P. | — | Travel and Lodging | Cash or cash equivalent | $63.22 | General |
| 12/18/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,760.00 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Travel and Lodging | Cash or cash equivalent | $386.97 | General |
| Category: DERMATOLOGY | ||||||
| 12/18/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Travel and Lodging | Cash or cash equivalent | $367.19 | General |
| Category: DERMATOLOGY | ||||||
| 12/18/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $126.62 | General |
| Category: DERMATOLOGY | ||||||
| 12/18/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Immunology | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $8.71 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: Dermatology | ||||||
| 12/14/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Dermatology | ||||||
| 12/14/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Travel and Lodging | Cash or cash equivalent | $144.86 | General |
| Category: Dermatology | ||||||
| 12/14/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $134.33 | General |
| Category: Dermatology | ||||||
| 12/14/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $81.90 | General |
| Category: Inflammation | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $26,620 | 15 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $2,387 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,153 | 4,629 | $491,465 | $112,358 |
| 2022 | 15 | 1,374 | 1,879 | $607,275 | $134,747 |
| 2021 | 14 | 977 | 1,318 | $439,115 | $103,607 |
| 2020 | 1 | 11 | 11 | $3,410 | $648.98 |
Total Patients
3,515
Total Services
7,837
Medicare Billing
$351,360
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 258 | 370 | $107,501 | $25,807 | 24.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 189 | 189 | $76,380 | $17,269 | 22.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 176 | 209 | $70,244 | $17,052 | 24.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 92 | 125 | $53,034 | $12,271 | 23.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 85 | 100 | $43,152 | $9,153 | 21.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 56 | 56 | $33,744 | $7,591 | 22.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 96 | 118 | $29,950 | $5,466 | 18.3% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 13 | 16 | $15,134 | $4,294 | 28.4% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2023 | 14 | 3,000 | $14,850 | $3,897 | 26.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 20 | 26 | $16,014 | $3,680 | 23.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 56 | 306 | $12,393 | $1,777 | 14.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 30 | 35 | $6,223 | $1,541 | 24.8% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 22 | 22 | $5,288 | $1,148 | 21.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 15 | $2,988 | $739.34 | 24.7% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 15 | 16 | $3,410 | $652.46 | 19.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 17 | 26 | $1,160 | $19.05 | 1.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 281 | 382 | $103,220 | $26,486 | 25.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 182 | 234 | $91,720 | $22,621 | 24.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 212 | 247 | $64,220 | $16,851 | 26.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 190 | 190 | $78,010 | $15,962 | 20.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 104 | 104 | $63,320 | $12,425 | 19.6% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 48 | 61 | $37,210 | $8,756 | 23.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 73 | 87 | $39,600 | $7,915 | 20.0% |
| 96920 | Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | Office | 2022 | 11 | 52 | $36,400 | $7,724 | 21.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 105 | 131 | $35,370 | $6,613 | 18.7% |
About Michael Cameron
Michael Cameron is a Dermatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/25/2015. The National Provider Identifier (NPI) number assigned to this provider is 1912391186.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Cameron has received a total of $1.9M in payments from pharmaceutical and medical device companies, with $767,048 received in 2024. These payments were reported across 2,722 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Cameron has provided services to 3,515 Medicare beneficiaries, totaling 7,837 services with total Medicare billing of $351,360. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location New York, NY
- Active Since 03/25/2015
- Last Updated 11/14/2023
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1912391186
Products in Payments
- RINVOQ (Biological) $327,597
- VTAMA (Drug) $204,212
- DUPIXENT (Biological) $204,149
- Sotyktu (Drug) $174,031
- ADBRY (Biological) $141,031
- Otezla (Drug) $127,908
- Bimzelx (Biological) $76,851
- TALTZ (Drug) $71,354
- OLUMIANT (Drug) $66,992
- OPZELURA (Drug) $64,607
- SKYRIZI (Biological) $63,940
- ILUMYA (Biological) $40,037
- Olumiant (Drug) $32,614
- Zoryve (Drug) $29,407
- LITFULO (Drug) $24,148
- YCANTH (Drug) $23,126
- TAPINAROF (Drug) $16,938
- Winlevi (Drug) $14,277
- CIBINQO (Drug) $12,453
- JUBLIA (Drug) $10,365
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in New York
David Cohen, M.d, M.D
Dermatology — Payments: $3.1M
Dermatology $3.1M
Dr. Amy Wechsler, M.d, M.D
Dermatology — Payments: $2.8M
Dermatology $2.8M
Dr. Alexandra Golant, M.d, M.D
Dermatology — Payments: $2.7M
Dermatology $2.7M
Emma Guttman, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Dr. Joshua Zeichner, Md, MD
Dermatology — Payments: $2.1M
Dermatology $2.1M
Dr. Mark Lebwohl
Dermatology — Payments: $2.0M
Dermatology $2.0M